Status:
COMPLETED
Effect of Age on Latanoprost 0.005% in Patients With Glaucoma
Lead Sponsor:
Yale University
Collaborating Sponsors:
Pfizer
Conditions:
Glaucoma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Latanoprost is a commonly used treatment for glaucoma. Because of its mechanism of action, it is plausible that the age of a patient using the medication may affect its efficacy and time of onset. We...
Detailed Description
Latanoprost is a topical ocular hypotensive medication with a well established safety and efficacy profile. Its effect is mediated by an increase in uveoscleral outflow, due to enzymatic degradation o...
Eligibility Criteria
Inclusion
- diagnosis of open angle glaucoma,
- pseudoexfoliation glaucoma, pigmentary glaucoma or ocular hypertension in one or both eyes;
- IOP above their target pressure as determined by a glaucoma specialist;
- willingness to participate in the study.
Exclusion
- hypersensitivity to any of the components of the treatment medication;
- previous use of topical prostaglandins;
- documented ocular infection or intraocular inflammation within the past year;
- previous filtering surgery or complicated cataract surgery;
- active corneal disease;
- presence of cystoid macular edema;
- laser trabeculoplasty or any other ocular laser procedure within the past three months.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00224289
Start Date
March 1 2005
End Date
April 1 2009
Last Update
December 10 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale Eye Center
New Haven, Connecticut, United States, 06510